| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 1,602 | 1,594 | 1,513 | 1,582 |
| Cost of sales | 745 | 720 | 672 | 659 |
| Gross profit | 857 | 874 | 841 | 923 |
| Selling, general and administrative | 415 | 453 | 420 | 422 |
| Research and development | 84 | 95 | 96 | 111 |
| Acquired in-process research and development and milestones | 0 | 0 | 6 | 51 |
| Restructuring costs | 0 | 2 | 86 | 0 |
| Interest expense | 128 | 131 | 124 | 126 |
| Exchange losses | -17 | 1 | 4 | -6 |
| Other (income) expense, net | 30 | 35 | -12 | 0 |
| Income before income taxes | 243 | 229 | 101 | 207 |
| Income tax expense (benefit) | 83 | 84 | 14 | -152 |
| Net income | 160 | 145 | 87 | 359 |
| Basic (in dollars per share) | 0.61 | 0.56 | 0.34 | 1.39 |
| Basic (in shares) | 259,975,000 | 259,939,000 | 257,862,000 | 257,498,000 |
| Diluted (in dollars per share) | 0.61 | 0.56 | 0.33 | 1.38 |
| Diluted (in shares) | 260,653,000 | 260,156,000 | 261,001,000 | 259,757,000 |
Organon & Co. (OGN)
Organon & Co. (OGN)